Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
204 studies found for:    Open Studies | "Hodgkin Disease"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Hodgkin Disease"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Condition: Hodgkin Disease
Interventions: Drug: Brentuximab vedotin;   Drug: Doxorubicin;   Drug: Vinblastine;   Drug: Dacarbazine
2 Recruiting Brazilian Prospective Hodgkin Lymphoma Registry
Conditions: Hodgkin Lymphoma;   Hodgkin Disease
Intervention:
3 Recruiting Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
Condition: Hodgkin's Disease
Intervention:
4 Recruiting Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE
Condition: Hodgkin Disease
Interventions: Drug: Brentuximab Vedotin;   Drug: Etoposide;   Drug: Carboplatine;   Drug: Ifosfamide
5 Not yet recruiting A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response
Condition: Hodgkin Disease
Interventions: Biological: Nivolumab;   Biological: brentuximab vedotin;   Biological: bendamustine
6 Recruiting A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
Condition: Hodgkin Disease
Interventions: Drug: brentuximab vedotin;   Drug: bendamustine;   Drug: dacarbazine;   Drug: nivolumab
7 Recruiting Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A
Condition: Hodgkin Disease
Interventions: Drug: ABVE-PC;   Drug: DECA
8 Recruiting Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
Conditions: Lymphoma, Non-Hodgkin;   Hodgkin's Disease
Intervention:
9 Recruiting Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: Stanford V Chemotherapy;   Radiation: Radiation Therapy
10 Recruiting Brentuximab for Newly Diagnosed Hodgkin Disease
Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Rituximab
11 Recruiting Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Adriamycin;   Drug: Dacarbazine
12 Recruiting A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.
Condition: Hodgkin Lymphoma
Intervention: Drug: Brentuximab Vedotin
13 Recruiting Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Condition: Hodgkin's Lymphoma
Intervention: Drug: Temsirolimus
14 Recruiting HD17 for Intermediate Stage Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone);   Drug: ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine);   Radiation: 30Gy IF-RT (Involved-Field Radiotherapy);   Radiation: 30Gy IN-RT (Involved-Node Radiotherapy)
15 Recruiting GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: AFM13
16 Recruiting Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Reduced Intensity Conditioning
17 Recruiting Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma
Condition: Hodgkins Lymphoma
Intervention: Biological: allogeneic donor derived LMP specific cytotoxic T-lymphocyte
18 Recruiting Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma
Condition: Classical Hodgkin Lymphoma
Intervention: Other: Digital Polymerase Chain Reaction
19 Recruiting Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
Condition: Hodgkins Lymphoma
Intervention: Biological: Avelumab
20 Recruiting Genetic Study of Families With High Frequency of Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.